Esperion Therapeutics | ESPR - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 4.73B 1.08B 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.83B 130M 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Cipla INR 9.77B 6.21B 2025-12
CSL USD 2.64B 1.97B 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Geron USD -10.79M 3.1M 2025-12
Grifols EUR 320.55M 91.01M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
Merck USD -1.88B 8.12B 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sanofi EUR 1.94B 239M 2026-03
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12